Trial · NCT03642964
A Study in Patients With Major Depressive Disorder
NCT03642964, Phase 2, Unknown, Chase Therapeutics Corporation
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study in Patients With Major Depressive Disorder. Trials, record NCT03642964. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03642964
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study in Patients With Major Depressive Disorder
- NCT number
- NCT03642964
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 24 participants, estimated
- Lead sponsor
- Chase Therapeutics Corporation
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- CTC-501
- First posted
- 2018-08-22
- Last updated
- 2024-07-11
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tolerability will be assessed by the determination of a Maximum Tolerated Dose of pramipexole | multiple over 8 weeks | All subjects will be assessed for dose limiting side effects such as nausea, vomiting and diarrhea. |
| Secondary | Safety will be assessed by Incidence of Treatment-Emergent Adverse Events | Multiple over 8 weeks | Incidence and nature of adverse events; vital signs; weight ; physical examination changes; clinical laboratory evaluations; ECG. |
| Secondary | The Montgomery-Åsberg Depression Rating Scale | Multiple over 7 weeks | Change from baseline in the following depression scale; The Montgomery-Åsberg Depression Rating Scale (abbreviated MADRS) is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorder. Mean change from baseline on the Montgomery Asberg Depression Rating Scale. (MADRS) Relative to Standard of Care. The MADRS is a 10 item scale with each item scored from 0 to 6 where 0 represents minimal symptoms and 6 represents maximum response to that item. The total MADRS score ranges from 0 to 60. |
| Secondary | Clinical Global Impression - Severity scale | Multiple over 7 weeks | Change from baseline in the following depression scales.Mean change from baseline on the CGI-Severity of Illness(CGI-SI) score overtime.The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. o CGI-Global Improvement (CGI-GI) score at the end of 8-week maintenance period |
| Secondary | Clinical Global Impression - Improvement scale | at week 8 only | Change from baseline in the following depression scales;The Clinical Global Improvement - CGI-Global Improvement (CGI-GI) score at the end of 8-week maintenance period is a one question scale comparing who the clinician feels the patient's condition has changed from baseline. The scale is from 0-7 (0 being 'not assessed' to 7 being 'very much worse'. |
| Secondary | Pharmacokinetics will measure plasma concentrations of pramipexole and ondansetron | Multiple over 7 weeks | Plasma concentrations of pramipexole and ondansetron will be measured at various times throughout the study in only pramipexole group. Both groups will have blood draws. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03642964
GET https://conductscience.org/api/trials/v1/NCT03642964/registered